University of Minnesota

Rutgers, the State University of New Jersey

Wellgen, Inc.

Ann M Bode

Zigang Dong

Kanamata Reddy

Chi-Tang Ho

Naisheng Bai

Slavik Dushenkov

Eunmiri Roh

Srinivasa Reddy Kanamata Reddy

Young-Yeon Cho

Dong Joon Kim

An example technique for treating a skin cancer condition includes administering a therapeutically effective amount of a p53-related protein kinase (PRPK) inhibitor to a patient having skin cancer or having a high risk of developing skin cancer. An example composition includes a therapeutically effective amount of a PRPK inhibitor for treating a skin cancer condition. An example composition includes a pharmaceutically effective amount of at least one anti-solar ultraviolet (anti-sUV) combination for preventing a skin cancer condition. The at least one anti-sUV combination is chosen from the combinations: avobenzone and octinoxate; octocrylene and zinc oxide; avobenzone, octocrylene, and titanium dioxide; or avobenzone, octocrylene, and zinc oxide.

Skin care formulations and skin cancer treatment

The invention provides methods, uses and compounds for treating cancers. For example, certain embodiments provide a method for treating cancer in a mammal comprising administering to the mammal an effective amount of 3,5,7,8,4'-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. Certain other embodiments of the invention provide methods for inactivating ornithine decarboxylase (ODC) in a cell comprising contacting the cell in vitro or in vivo with an effective amount of 3,5,7,8,4&#x2032;-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. The invention also provides a dermal product comprising 3,5,7,8,4&#x2032;-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof, wherein the product prophylactically or therapeutically treats sunburn or other sun exposure and/or skin cancer in a mammal. 

Methods of treating cancer with herbacetin

The invention provides a compound of formula I: or a salt thereof, wherein R, R, R, Rand ring A have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as anti-cancer agents.

Therapeutic compounds

The invention provides compounds of the formula: and salts thereof that are useful as intermediates for preparing corresponding compounds of formula I: that are useful for treating conditions associated with Aurora B kinase activity (e.g. cancer).

Aurora kinase inhibitors

Compounds are disclosed which are effective for inhibiting &#x3b2;-catenin or disrupting a &#x3b2;-catenin/Tcf-4 complex, and for causing effective attenuation of colon carcinogenesis. The compounds may be effective treatment for colorectal cancer (CRC) when administered in an effective dose to a patient afflicted therewith.

Inhibitors of beta-catenin in treatment of colorectal cancer

The invention provides a compound of formula I: or a salt thereof, wherein ring A and R-Rhave any of the values defined in the specification. The compounds have activity as Aurora B kinase inhibitors and are useful for treating conditions associated with Aurora B kinase activity (e.g. cancer). 

In one aspect, the present invention provides compounds having formula I or IV as shown below: as further defined herein. In additional aspects, the present invention provides compositions and kits comprising the compounds of the invention and methods for their use, for example, for the prevention or treatment of a cancer.

Growing community of inventors

Minneapolis, MN, United States of America

Ann M Bode